(Q39013086)

8 September 2017

1 reference

title

Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions (English)

1 reference

8 September 2017

1 reference

1 reference

C Hézode

1

1 reference

8 September 2017

9 November 2016

1 reference

Journal of Viral Hepatitis

8 September 2017

1 reference

8 September 2017

24

1 reference

8 September 2017

2

1 reference

8 September 2017

92-101

1 reference

Global epidemiology and genotype distribution of the hepatitis C virus infection

8 September 2017

1 reference

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

21 January 2018

1 reference

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

21 January 2018

1 reference

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

21 January 2018

1 reference

Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection

21 January 2018

1 reference

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

21 January 2018

1 reference

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

21 January 2018

1 reference

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

21 January 2018

1 reference

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

21 January 2018

1 reference

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

21 January 2018

1 reference

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

21 January 2018

1 reference

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

21 January 2018

1 reference

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

21 January 2018

1 reference

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

21 January 2018

1 reference

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

21 January 2018

1 reference

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

21 January 2018

1 reference

Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment

21 January 2018

1 reference

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen

21 January 2018

1 reference

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12635

1 reference

8 September 2017

1 reference

PubMed ID

27862695